In addition, clinical trials in a small group of patients validated effective tumor targeting and favorable biodistribution of MORAb-003, supporting its potential for radioimmunoscintigraphy, radioimmunotherapy, and targeted treatment of FRA-expressing cancers [77]. This evidence concerns the gene FOLR1 and neoplasm.